Beta

Climb bio, inc.CLYM.US Overview

US StockHealthcare
(No presentation for CLYM)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

CLYM AI Insights

CLYM Overall Performance

CLYM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CLYM Recent Performance

-2.53%

Climb bio, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

CLYM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check CLYM's Trend

CLYM Key Information

CLYM Valuation Metrics

CLYM Profile

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Price of CLYM

CLYM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CLYM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.72
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.72
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CLYM's latest earnings report released?

    The most recent financial report for Climb bio, inc. (CLYM) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CLYM's short-term business performance and financial health. For the latest updates on CLYM's earnings releases, visit this page regularly.

  • How much debt does CLYM have?

    As of the end of the reporting period, Climb bio, inc. (CLYM) had total debt of 541K, with a debt ratio of 0. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CLYM have?

    At the end of the period, Climb bio, inc. (CLYM) held Total Cash and Cash Equivalents of 35.69M, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CLYM's EPS continuing to grow?

    According to the past four quarterly reports, Climb bio, inc. (CLYM)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.25. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CLYM?

    Climb bio, inc. (CLYM)'s Free Cash Flow (FCF) for the period is -15.64M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 183.19% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CLYM?

    The latest valuation data shows Climb bio, inc. (CLYM) has a Price-To-Earnings (PE) ratio of -5.9 and a Price/Earnings-To-Growth (PEG) ratio of -0.1. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.